Artixio

ANVISA GMP Certification (CBPF) for Pharmaceutical Manufacturers in Brazil

ANVISA GMP certification (CBPF) for pharmaceutical manufacturers

The National Health Surveillance Agency (ANVISA) is Brazil’s regulatory authority for health products and services. It issues the Certificado de Boas Práticas de Fabricação (CBPF), which confirms that a manufacturing site meets Good Manufacturing Practices (GMP). ANVISA GMP certification matters because a valid CBPF is a prerequisite for marketing authorization of foreign-made medicines and active pharmaceutical ingredients (APIs) in Brazil. Manufacturers supplying this market need to understand how it works.

This article covers who requires a CBPF, the applicable ANVISA GMP requirements, the application and inspection process for domestic and foreign manufacturers, and certificate validity and renewal.

What Is ANVISA GMP Certification (CBPF)?

The CBPF is a document issued by ANVISA stating that an establishment meets the GMP technical requirements needed to market a product. Brazilian GMP certification is a certification of the establishment. It does not operate as a general licence to manufacture.

GMP compliance and certification are not the same thing:

  • GMP compliance is mandatory for all manufacturers of regulated products, whether or not a certificate has been issued.
  • CBPF certification is the formal attestation issued by ANVISA. ANVISA states that holding the certificate is not required for regular operation

The certificate is valid only for the approved factory and manufacturing activities. For medicines, it specifies the approved production lines and dosage forms (e.g., tablets, capsules, injections). For APIs, it is granted based on the approved manufacturing process or method of obtention.

Who Needs CBPF Certification in Brazil?

The regulation on CBPF certification in Brazil applies to manufacturers of medicines, APIs (including biological APIs) and other regulated products, whether located in Brazil or abroad seeking marketing authorization for their products in Brazil.

  • Domestic Pharmaceutical Manufacturers: Inspections of establishments in Brazil may be conducted by ANVISA or by state, district or municipal health surveillance bodies.
  • Foreign manufacturers: ANVISA GMP certification for foreign manufacturers is requested by a company legally established in Brazil. Foreign companies cannot deal directly with ANVISA on this.
  • API and biological manufacturers: Both chemical and biological API manufacturers require certification. Biological APIs are evaluated and certified separately based on their specific production methods.

ANVISA GMP Requirements for Pharmaceutical Manufacturers

The ANVISA GMP requirements for medicinal products are set out in RDC 658/2022. This regulation adopts the Good Manufacturing Practices (GMP) guidelines of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) as a minimum requirement. APIs and biological products are governed by separate regulations under RDC 654/2022 and IN 127/2022.

Core ANVISA Pharmaceutical Manufacturing Requirements are:

  • A pharmaceutical quality system with quality assurance.
  • Suitable premises, equipment and utilities.
  • Controlled production and quality control.
  • Documentation, validation and trained personnel.

In practice, inspection trouble rarely comes from a missing procedure. It comes from a written procedure that differs from what operators do on the floor or from validation records that do not match batch records.

How to Obtain ANVISA GMP Certification (CBPF)

The procedure comprises the following steps:

Step 1: Identify the Applicable CBPF Requirements

The manufacturer must determine the product category, the production line or method of obtention, and the location of the establishment.

Step 2: Submit the application

The Brazilian applicant files a petition in ANVISA’s Solicita system, uploads the documents listed for that petition subject and pays the inspection fee. The required documents depend on the petition subject, so check the list in ANVISA’s Consulta de Assuntos before filing.

Step 3: Undergo Inspection or Regulatory Assessment

ANVISA analyses the file and may inspect the site.

Step 4: Address Inspection Deficiencies

The manufacturer is required to respond to findings and implement corrective actions. Refusing or obstructing ANVISA inspections, or lacking proof of compliance, can lead to application being denied.

Step 5: Receive the decision

The result is published in the Diário Oficial da União (DOU), Brazil’s Official Gazette.

The estimated average processing time for ANVISA GMP certification is 118 calendar days.

ANVISA GMP Inspection Process for Foreign Manufacturers

ANVISA runs international inspections of foreign medicine and API manufacturers. The Brazilian legal representative is responsible for requesting the certificate and its renewals every two years.

Depending on a risk analysis, ANVISA may decide between the following routes:

Route What it means
On-site inspection ANVISA inspects the foreign manufacturing site
Documentary assessment
Certificate issued on documents and reliable evidence, without a visit

Regulatory reliance is a third, separate and optional route. ANVISA may use inspection reports and certificates from Equivalent Foreign Regulatory Authorities (AREE).

An AREE must be a member of both PIC/S and ICH, and ANVISA’s Board must approve it. ANVISA publishes the approved authorities in a list annexed to IN 292/2024 Annexes I and II. It currently names 42 jurisdictions, including the US FDA, the European Medicines Agency (EMA), the UK’s MHRA, Health Canada and Swissmedic. No authority has yet been approved for mutual recognition, the highest level of reliance.

Reliance level Basis of ANVISA’s decision Status
Partial Full review of the foreign inspection report or other AREE information
Available for Annex I authorities
Full Simplified review of the report, or acceptance of part or all of the foreign GMP certificate
Available for Annex I authorities
Mutual recognition Foreign decision adopted automatically under a bilateral agreement No authority approved

Reliance does not displace ANVISA’s inspection authority. ANVISA may inspect any manufacturer at any time, independently of the certification process and the level of reliance, and refusal to receive an inspection may result in a change of decision.

CBPF Validity and Renewal

A CBPF is valid for two years from the date of its publication in the DOU. The CBPF renewal requirements in Brazil are as follows:

  • The renewal petition must be filed between 270 and 180 days before expiry of the current certificate for certification to continue without interruption.
  • Renewal is subject to a risk-based assessment, which may result in an inspection or a documentary review.
  • ANVISA may cancel a certificate at any time where a technical opinion show non-compliance with GMP requirements.

The validity of any certificate may be verified in ANVISA’s official certificate database.

A CBPF stays valid only while GMP compliance is maintained, and requirements can change during its two-year life. At Artixio, we built our regulatory intelligence platform, Qurious RI, to help with this. Its Impact Overview feature shows how a new guideline or announcement affects a company’s existing SOP and what actions are needed.

Why Is ANVISA CBPF Certification Important for Pharmaceutical Companies?

For foreign medicinal products and APIs, a valid CBPF is a prerequisite for marketing authorization. GMP certification in Brazil provides documented evidence of GMP compliance for ANVISA’s wider regulatory review. The CBPF does not, on its own, grant marketing authorization, and product registration remains a separate ANVISA procedure. Keeping GMP compliance between inspections matters because the certificate can be cancelled at any time.

Conclusion

ANVISA GMP certification connects a manufacturing establishment to Brazilian market access and remains valid only while GMP compliance is maintained. Manufacturers must file renewals within the prescribed window and ensure that documentation reflects actual practice.

For support with CBPF applications, inspection readiness or Brazilian pharmaceutical regulatory compliance, explore Artixio’s GMP consulting services or contact Artixio at info@artixio.com.

FAQs

Q1. Is a CBPF mandatory in Brazil?

GMP compliance is always mandatory, but ANVISA says holding the certificate is not required for regular operation. A valid CBPF is, however, a prerequisite for marketing authorization of foreign medicines and APIs.

Q2. How long is a CBPF valid?

Two years from its publication in the DOU. To avoid a gap, file the renewal 270 to 180 days before expiry.

Q3. Can foreign manufacturing sites get a CBPF?

Yes. A company legally established in Brazil files the request, and ANVISA assesses the site by inspection, documentary assessment or reliance.

Q4. How can manufacturers keep track of changes to ANVISA GMP requirements?

ANVISA publishes new resolutions and normative instructions in the DOU and on its website, so these are the authoritative sources to check. At Artixio, we also offer Qurious RI, a regulatory intelligence platform that brings official-source updates into one place.

Q5. Does the CBPF grant marketing authorization?

No. It is one prerequisite for foreign medicines and APIs, and product registration is a separate ANVISA process.

Q6. Does a foreign GMP certificate replace the CBPF?

No. ANVISA issues the CBPF itself. It may use reports from approved foreign authorities to support its decision, but only for authorities listed in IN 292/2024, and it can still inspect at any time.

Get in touch

×